Pharmaceuticals Government Tenders in Latvia

Registration, quality assurance and the shape of a medicines contract

A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programmes -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.

Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.

The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and programme funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.

This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.

Who buys pharmaceuticals in Latvia?

GlobalGov holds 124 pharmaceuticals records from 43 distinct buying organisations in Latvia. The most frequent publishers are AS "Latvijas valsts meži" (13 records); Latvijas Valsts koksnes ķīmijas institūts (8 records); International buyer (8 records); Latvijas Lauksaimniecības universitāte (7 records); Valsts aizsardzības loģistikas un iepirkumu centrs (6 records); Latvijas Biozinātņu un tehnoloģiju universitāte (5 records). Between them the 6 largest account for 38% of everything published, so buying here is spread across many separate authorities.

What are pharmaceuticals contracts worth in Latvia?

73 of the 124 records publish a contract value. The median is $216,000 and the largest single published value is $9.4M. By size, 22 under $100k, 41 between $100k and $1M, 10 between $1M and $10M. The remaining 51 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.

How long do bidders get to respond to pharmaceuticals tenders in Latvia?

Across the 47 Latvia pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 34 days. A quarter of them allowed 31 days or fewer and a quarter stayed open for more than 36. Not one of them closed within a fortnight of being published, so the window on this market is consistently workable.

How often are pharmaceuticals tenders published in Latvia?

Latvia published 13 notices in this category in the last twelve months. That is 41% fewer than the 22 published in the twelve months before that. Over the last three years there were 50, spread across 50 separate months of activity since 7 February 2017. September is historically the busiest month. The most recent was published 8 September 2026.

How does Latvia compare with other pharmaceuticals markets?

Among the 39 countries where GlobalGov holds a comparable pharmaceuticals market, Latvia ranks 28th by number of records. The largest is Germany (4,115 records against 124 here). Within Latvia itself, pharmaceuticals is the 23rd largest of the 47 procurement categories tracked here.

Where do the Latvia pharmaceuticals records on this page come from?

These 124 records are collected from 1 official source: TED (124). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-10-01.

Open Pharmaceuticals tenders in Latvia

Showing 3 of the 3 notices open in this category today. Openness uses the same definition as the Latvia market page: active, not marked awarded, cancelled, closed or expired, and either closing in the future or published within the last 90 days with no stated closing date.

Other procurement categories in Latvia

Pharmaceuticals procurement in other markets